161 related articles for article (PubMed ID: 34352997)
1. Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy.
Chen Y; Huang H; Liu Y; Wang Z; Wang L; Wang Q; Zhang Y; Wang H
Cancer Res Treat; 2022 Apr; 54(2):362-374. PubMed ID: 34352997
[TBL] [Abstract][Full Text] [Related]
2. Development of PD-1 blockade peptide-cell conjugates to enhance cellular therapies for T-cell acute lymphoblastic leukemia.
Wang Q; Huang H; Liang P; Wang L; Zheng J; Zhang Y; Wang H
Med Oncol; 2023 Dec; 41(1):14. PubMed ID: 38078948
[TBL] [Abstract][Full Text] [Related]
3. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
6. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor.
Li Q; Quan L; Lyu J; He Z; Wang X; Meng J; Zhao Z; Zhu L; Liu X; Li H
Oncotarget; 2016 Oct; 7(40):64967-64976. PubMed ID: 27533458
[TBL] [Abstract][Full Text] [Related]
7. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
8. Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC).
Huang X; Zhang J; Li X; Huang H; Liu Y; Yu M; Zhang Y; Wang H
Int Immunopharmacol; 2018 Jun; 59():127-133. PubMed ID: 29653410
[TBL] [Abstract][Full Text] [Related]
9. Structure-Guided Discovery of PD-1/PD-L1 Interaction Inhibitors: Peptide Design, Screening, and Optimization via Computation-Aided Phage Display Engineering.
Tseng TS; Lee CC; Chen PJ; Lin CY; Chen WC; Lee YC; Lin JH; Chen KW; Tsai KC
J Chem Inf Model; 2024 Mar; 64(5):1615-1627. PubMed ID: 38356220
[TBL] [Abstract][Full Text] [Related]
10. Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress.
Qin Y; Meng X; Li L; Liu C; Gao F; Yuan X; Huang Y; Zhu Y
Eur J Pharmacol; 2023 Dec; 960():176144. PubMed ID: 37866745
[TBL] [Abstract][Full Text] [Related]
11. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).
Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW
ACS Chem Biol; 2020 Jun; 15(6):1630-1641. PubMed ID: 32352272
[TBL] [Abstract][Full Text] [Related]
12. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
Zyla E; Musielak B; Holak TA; Dubin G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity.
Tooyserkani R; Rasaee MJ; Bandehpour M; W P M Löwik D
J Drug Target; 2021 Aug; 29(7):771-782. PubMed ID: 33478285
[TBL] [Abstract][Full Text] [Related]
14. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
[TBL] [Abstract][Full Text] [Related]
16. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
17. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
18. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
[TBL] [Abstract][Full Text] [Related]
19. Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Li C; Zhang N; Zhou J; Ding C; Jin Y; Cui X; Pu K; Zhu Y
Cancer Immunol Res; 2018 Feb; 6(2):178-188. PubMed ID: 29217732
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction.
Rui M; Zhang W; Mi K; Ni H; Ji W; Yu X; Qin J; Feng C
Int J Biol Macromol; 2023 Dec; 253(Pt 2):126811. PubMed ID: 37690647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
